Key Points Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its losses have been rising in recent years as has its share count -- a notable concern for investors. 10 stocks we like better than Recursion Pharmaceuticals › Artificial intelligence (AI) has the potential to transform all sectors and industries throughout the economy. Investing in companies th ...

Core Insights - Novo Nordisk has informed employees about job cuts across most of its locations, with the pace of notifications varying based on local laws [1] Group 1 - The company is undergoing significant workforce reductions as part of its restructuring efforts [1] - CEO Mike Doustdar communicated the changes through a post, indicating a strategic shift within the organization [1] - The job cuts are part of a broader trend in the pharmaceutical industry, reflecting ongoing adjustments to market conditions [1]

Bavarian Nordic announced on Friday a new contract with the European Commission, allowing countries across Europe to buy up to eight million doses of its smallpox and mpox vaccine over the next four y... ...

These stocks may be down as of late, but investors shouldn't count them out in the long run.It can take a while for growth stocks to reach their full potential, which is why they can make for good long-term options to hang on to. Along the way, however, they can encounter difficulties that send their valuations down. But those declines in value could prove to be temporary, and that's why buying solid growth stocks when they are down can be a great move in the long run.Three stocks that look to have solid gr ...

新华制药公告，近日收到国家药品监督管理局核准签发的阿仑膦酸钠口服溶液《药品注册证书》。该药 品适用于治疗绝经后妇女的骨质疏松症，以预防髋部和脊柱骨折（椎骨压缩性骨折）和男性骨质疏松以 增加骨量。2024年阿仑膦酸钠在包括中国公立医院、公立基层医疗机构、零售药店在内的三大终端销售 额达人民币7.2亿元。 ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received the drug registration certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration, indicating a significant advancement in its product offerings for osteoporosis treatment [1] Company Summary - The approval of Alendronate Sodium Oral Solution is aimed at treating osteoporosis in postmenopausal women and preventing hip and spinal fractures, as well as increasing bone mass in men with osteoporosis [1]

Core Points - Bavarian Nordic A/S has been awarded a joint procurement contract by the European Commission to supply up to 8 million doses of its MVA-BN smallpox/mpox vaccine [1][8] - The two-year agreement, which can be extended for an additional two years, aims to ensure continuous access to the vaccine across Europe, with participation confirmed from the European Commission and 20 countries [2][8] - Approximately 1.1 million doses have already been committed, with the first 750,000 doses expected to be supplied in 2026 [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, particularly in the area of smallpox and mpox [7] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in several countries, including the U.S., Canada, and the EU [6] - The company has been collaborating with HERA since 2022 to support public health responses to mpox outbreaks and to stockpile vaccines against potential smallpox reemergence [5]

Group 1 - The core viewpoint of the articles highlights a significant surge in the innovative drug sector within the A-share market, particularly on October 31, where several stocks, including Shuyat and Sanofi, hit the 20% daily limit increase [1] - The A-share market experienced fluctuations, with the ChiNext index dropping over 2%, and the total trading volume in the Shanghai and Shenzhen markets reaching 2.32 trillion yuan, a decrease of 103.9 billion yuan compared to the previous trading day [1] - The introduction of the "Commercial Insurance Innovative Drug Directory" mechanism during the national medical insurance negotiations is expected to benefit innovative drugs that are highly innovative and clinically valuable but are not yet included in the basic directory [1] Group 2 - According to Guosen Securities, the Chinese innovative drug industry is showing a long-term positive development trend, particularly evident in the explosive growth of BD transactions in recent years [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners overseas and subsequent global clinical data readings enhancing the certainty of commercialization in the global market [2] - The long-term logic of investing in innovative drugs is favored, with a focus on stocks that are showing signs of bottom reversal [2]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The prolonged slowdown in biotechnology startup funding has given an opportunity for a specific set of investors to step in: corporate venture firms. Data compiled by BioPharma Dive show that venture funds associated with Novo Holdings, Eli Lilly and Sanofi have been among the most active backers of privately held companies this year. Novo Holdings, for exampl ...

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8% Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 2 ...